Invetx

We are thrilled to announce that Invetx has agreed to be acquired by Dechra Pharmaceuticals, a global leader in animal health, for up to $520 million on a cash-free and debt-free basis. Our pipeline of monoclonal antibody therapeutics for companion animals and our species-specific, half-life extension technology platform will complement and differentiate Dechra’s broad portfolio of specialty therapeutics for companion animals. We want to thank our numerous veterinary collaborators and their canine and feline patients, technology partners, investors and consultants who have helped create the value at Invetx leading to this important inflection point. The acquisition remains subject to antitrust approval and other customary closing conditions. https://lnkd.in/gWZgvhnM #veterinarybiotherapeutics #companionanimals #animalhealth

Come hear our senior vice president of CMC and manufacturing, Dr. Krishnan Sampath, who will be the featured speaker on the upcoming webinar “Road Map for Drug Product Development and Manufacturing of Biologics.” Sponsored by the International Pharmaceutical Federation (FIP), the webinar will be held on February 29th, 2024 at 3 pm CET (9 am EST/6 am PST). Read more details and register here: https://lnkd.in/dMxFr-8h. #veterinaryantibodies #animalhealth #biologicsdrugdevelopment

"Wishing a very merry holiday season to all of our collaborators and supporters from the team at Invetx!

Recent market research showed that a majority of pet owners and veterinarians would switch to a longer-acting, higher-priced therapeutic to treat chronic osteoarthritis pain in dogs and cats for greater convenience and compliance. This study validates Invetx’s innovative patented half-life extension platform, which extends dosing intervals by at least two to three months. The technology is being applied to our portfolio of monoclonal antibody (mAb) therapeutics for chronic conditions in cats and dogs. The study, which included approximately 2,000 companion animal veterinarians and pet owners, also showed a significantly higher incidence of osteoarthritis/chronic pain in dogs and cats than previously thought (30-40% v. 20 %). Read more here. https://lnkd.in/gsvp7_Nc

Congratulations to Krishnan Sampath, PhD, our senior vice president of CMC and manufacturing, and co-author of the recent publication “Roadmap for Drug Product Development and Manufacturing of Biologics” in the Journal of Pharmaceutical Sciences (November 07, 2023, https://lnkd.in/gA3sTZJW). The paper establishes a unified framework and roadmap for successful biologics drug development, from early development to manufacturing and commercialization. At Invetx, Dr. Sampath is applying his deep expertise to help advance our portfolio of differentiated and best-in-class mAb therapeutics for cats and dogs at an affordable cost. His team has established a 3rd party manufacturing network for veterinary mAbs under FDA/EMA as well as USDA jurisdiction, successfully progressed one product candidate to GMP production and introduced advanced technology platforms to further reduce cost-of-goods.